Holly Longstaff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Holly Longstaff has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Brenda Lucas
BC Provincial Health Services Authority (Longstaff, Schichter); University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (Longstaff), Vancouver, C.-B.; Canadian Critical Care Trials Group (Lucas), Markham, Ont.; Faculté de médecine (Murthy), University of British Columbia, Vancouver, C.-B.; Direction des politiques scientifiques (Flamenbaum), Instituts de recherche en santé du Canada, Ottawa, Ont
2 shared publicationsBrittney Schichter
BC Provincial Health Services Authority (Longstaff, Schichter); University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (Longstaff), Vancouver, C.-B.; Canadian Critical Care Trials Group (Lucas), Markham, Ont.; Faculté de médecine (Murthy), University of British Columbia, Vancouver, C.-B.; Direction des politiques scientifiques (Flamenbaum), Instituts de recherche en santé du Canada, Ottawa, Ont
2 shared publicationsJaime Flamenbaum
BC Provincial Health Services Authority (Longstaff, Schichter); University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (Longstaff), Vancouver, C.-B.; Canadian Critical Care Trials Group (Lucas), Markham, Ont.; Faculté de médecine (Murthy), University of British Columbia, Vancouver, C.-B.; Direction des politiques scientifiques (Flamenbaum), Instituts de recherche en santé du Canada, Ottawa, Ont
2 shared publicationsSrinivas Murthy
BC Provincial Health Services Authority (Longstaff, Schichter); University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (Longstaff), Vancouver, C.-B.; Canadian Critical Care Trials Group (Lucas), Markham, Ont.; Faculté de médecine (Murthy), University of British Columbia, Vancouver, C.-B.; Direction des politiques scientifiques (Flamenbaum), Instituts de recherche en santé du Canada, Ottawa, Ont
2 shared publications- Agnes Black
Providence Health Care
1 shared publication - Alice Virani
Department of Medical Genetics, Faculty of Medicine University of British Columbia Vancouver British Columbia Canada
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (38) , E1277-E1290
Éléments fondamentaux de la documentation du consentement à la recherche clinique au Canada : orientation stratégique
Les formulaires de consentement sont devenus trop longs et n’aident souvent pas les gens à comprendre les risques liés à leur participation à la recherche, se concentrant plutôt sur la réduction des risques pour les établissements de recherche. Sous les auspices des Instituts de recherche en santé du Canada et du Groupe canadien de recherche en soins intensifs, nous avons relevé un ensemble d’éléments fondamentaux des documents de consentement des personnes participantes à utiliser dans la recherche clinique et nous les présentons sous forme de modèle de formulaire de consentement. L’équipe principale chargée de l’élaboration des directives était composée d’experts et expertes des aspects juridiques et éthiques de la recherche et d’une scientifique spécialiste des essais cliniques. Nous avons procédé à un examen dirigé afin de dresser une liste des exigences réglementaires, politiques et d’orientation applicables à la documentation du consentement éclairé pour les recherches menées avec des êtres humains au Canada. Nous avons utilisé une analyse des lacunes pour relever les éléments requis dans un formulaire de consentement à la recherche, sur la base de ces documents et en comparaison avec 10 modèles de formulaires de consentement éclairé existants de comités d’éthique de la recherche (CER). Les directives, ainsi qu’un modèle de formulaire à remplir, ont été créés à l’aide de la participation d’un groupe consultatif pancanadien, de parties intéressées et d’un large public. Nous avons testé le modèle avec un petit groupe d’études dans plusieurs domaines de recherche. Notre processus de gestion des intérêts concurrents a respecté les principes du Guidelines International Network (GIN). Notre analyse des lacunes nous a permis de repérer 75 éléments fondamentaux des formulaires de consentement des personnes participantes à la recherche clinique, que nous avons regroupés en 6 catégories principales (renseignements destinés aux participantes ou aux participants potentiels sur la participation à la recherche en général et à l’étude en particulier; avantages et inconvénients de la participation; protection des données des personnes participantes; personnes-ressources; et consentement) dans un modèle de consentement à remplir. Étant donné que les études varient, les éléments particuliers ne doivent être inclus dans un formulaire de consentement à une étude que s’ils sont pertinents pour le type de recherche menée et les exigences en matière de conformité correspondantes relevées dans notre analyse des lacunes. Le modèle comprenant l’ensemble des éléments requis est destiné à être utilisé par tout chercheur ou toute chercheuse demandant l’approbation du CER pour documenter le consentement des personnes participantes et, lorsqu’il est appliqué en tenant compte de nos directives connexes, il est suffisant pour répondre aux exigences réglementaires en matière de recherche au Canada. Le recensement des éléments requis dans les formulaires de consentement vise à rationaliser les documents de consentement à travers le pays, à faciliter les projets multicentriques et à simplifier le processus d’approbation pour toutes les parties concernées.
- 10 November 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (38) , E1277-E1290
Open AccessÉléments fondamentaux de la documentation du consentement à la recherche clinique au Canada : orientation stratégique
Les formulaires de consentement sont devenus trop longs et n’aident souvent pas les gens à comprendre les risques liés à leur participation à la recherche, se concentrant plutôt sur la réduction des risques pour les établissements de recherche. Sous les auspices des Instituts de recherche en santé du Canada et du Groupe canadien de recherche en soins intensifs, nous avons relevé un ensemble d’éléments fondamentaux des documents de consentement des personnes participantes à utiliser dans la recherche clinique et nous les présentons sous forme de modèle de formulaire de consentement. L’équipe principale chargée de l’élaboration des directives était composée d’experts et expertes des aspects juridiques et éthiques de la recherche et d’une scientifique spécialiste des essais cliniques. Nous avons procédé à un examen dirigé afin de dresser une liste des exigences réglementaires, politiques et d’orientation applicables à la documentation du consentement éclairé pour les recherches menées avec des êtres humains au Canada. Nous avons utilisé une analyse des lacunes pour relever les éléments requis dans un formulaire de consentement à la recherche, sur la base de ces documents et en comparaison avec 10 modèles de formulaires de consentement éclairé existants de comités d’éthique de la recherche (CER). Les directives, ainsi qu’un modèle de formulaire à remplir, ont été créés à l’aide de la participation d’un groupe consultatif pancanadien, de parties intéressées et d’un large public. Nous avons testé le modèle avec un petit groupe d’études dans plusieurs domaines de recherche. Notre processus de gestion des intérêts concurrents a respecté les principes du Guidelines International Network (GIN). Notre analyse des lacunes nous a permis de repérer 75 éléments fondamentaux des formulaires de consentement des personnes participantes à la recherche clinique, que nous avons regroupés en 6 catégories principales (renseignements destinés aux participantes ou aux participants potentiels sur la participation à la recherche en général et à l’étude en particulier; avantages et inconvénients de la participation; protection des données des personnes participantes; personnes-ressources; et consentement) dans un modèle de consentement à remplir. Étant donné que les études varient, les éléments particuliers ne doivent être inclus dans un formulaire de consentement à une étude que s’ils sont pertinents pour le type de recherche menée et les exigences en matière de conformité correspondantes relevées dans notre analyse des lacunes. Le modèle comprenant l’ensemble des éléments requis est destiné à être utilisé par tout chercheur ou toute chercheuse demandant l’approbation du CER pour documenter le consentement des personnes participantes et, lorsqu’il est appliqué en tenant compte de nos directives connexes, il est suffisant pour répondre aux exigences réglementaires en matière de recherche au Canada. Le recensement des éléments requis dans les formulaires de consentement vise à rationaliser les documents de consentement à travers le pays, à faciliter les projets multicentriques et à simplifier le processus d’approbation pour toutes les parties concernées.
- Open Access
- 14 September 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (30) , E941-E952
Core elements of consent documentation for clinical research in Canada: guidance for policy
Consent forms have become too long and often do little to help people understand the risk elements of their participation in research, instead focusing on risk reduction for research institutions. Under the auspices of the Canadian Institutes of Health Research and the Canadian Critical Care Trials Group, we identified a core set of elements for participant consent documents to be used in clinical research and present these as a template consent form. Our guideline core team comprised experts in the legal and ethical aspects of research, and a clinical trialist-scientist. We conducted a directed review to compile a list of applicable regulatory, policy, and guidance requirements for the documentation of informed consent for research conducted with human participants in Canada. We used a gap analysis to identify the elements required in a research consent form, based on these documents and in comparison with 10 existing research ethics board (REB) informed-consent form templates. The guideline, as well as a fillable template for the form, was created with input from a pan-Canadian advisory group, interested parties, and broad public input. We tested the template with a small group of studies across several research domains. Our process for managing competing interests adhered to Guidelines International Network principles. From our gap analysis, we identified 75 core elements for participant consent forms in clinical research, which we have grouped under 6 main categories (i.e., information for potential participants about participating in research in general and in the particular study; harms and benefits of participation; protection of participant data; points of contact; and giving consent) in a fillable consent template. Because studies vary, specific elements should be included in a study consent form only if relevant to the type of research being conducted and the corresponding compliance requirements, as identified in our gap analysis. The template with the core set of required elements is intended to be used by any researcher applying for REB approval to document participant consent and, when applied with consideration of our associated guidance, is sufficient to meet regulatory requirements for research in Canada. Identifying the required elements for consent forms is intended to streamline consent documents across the country, facilitate multi-site projects, and simplify the approval process for all those involved.
- 14 September 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (30) , E941-E952
Open AccessCore elements of consent documentation for clinical research in Canada: guidance for policy
Consent forms have become too long and often do little to help people understand the risk elements of their participation in research, instead focusing on risk reduction for research institutions. Under the auspices of the Canadian Institutes of Health Research and the Canadian Critical Care Trials Group, we identified a core set of elements for participant consent documents to be used in clinical research and present these as a template consent form. Our guideline core team comprised experts in the legal and ethical aspects of research, and a clinical trialist-scientist. We conducted a directed review to compile a list of applicable regulatory, policy, and guidance requirements for the documentation of informed consent for research conducted with human participants in Canada. We used a gap analysis to identify the elements required in a research consent form, based on these documents and in comparison with 10 existing research ethics board (REB) informed-consent form templates. The guideline, as well as a fillable template for the form, was created with input from a pan-Canadian advisory group, interested parties, and broad public input. We tested the template with a small group of studies across several research domains. Our process for managing competing interests adhered to Guidelines International Network principles. From our gap analysis, we identified 75 core elements for participant consent forms in clinical research, which we have grouped under 6 main categories (i.e., information for potential participants about participating in research in general and in the particular study; harms and benefits of participation; protection of participant data; points of contact; and giving consent) in a fillable consent template. Because studies vary, specific elements should be included in a study consent form only if relevant to the type of research being conducted and the corresponding compliance requirements, as identified in our gap analysis. The template with the core set of required elements is intended to be used by any researcher applying for REB approval to document participant consent and, when applied with consideration of our associated guidance, is sufficient to meet regulatory requirements for research in Canada. Identifying the required elements for consent forms is intended to streamline consent documents across the country, facilitate multi-site projects, and simplify the approval process for all those involved.
- 11 July 2023
- Published by Taylor & Francis in Accountability in Research
- Vol. 31 (8) , 1-21
Deploying an ethics needs assessment to inform a navigational tool for research compliance pathways at a provincial Canadian health authority
- 11 July 2023
- Published by Taylor & Francis in Accountability in Research
- Vol. 31 (8) , 1-21
Deploying an ethics needs assessment to inform a navigational tool for research compliance pathways at a provincial Canadian health authority
- Open Access
- 6 August 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (15) , 9701
COVID-19 Outbreak: Understanding Moral-Distress Experiences Faced by Healthcare Workers in British Columbia, Canada
Pandemic-management plans shift the care model from patient-centred to public-centred and increase the risk of healthcare workers (HCWs) experiencing moral distress (MD). This study aimed to understand HCWs’ MD experiences during the COVID-19 pandemic and to identify HCWs’ preferred coping strategies. Based on a qualitative research methodology, three surveys were distributed at different stages of the pandemic response in British Columbia (BC), Canada. The thematic analysis of the data revealed common MD themes: concerns about ability to serve patients and about the risks intrinsic to the pandemic. Additionally, it revealed that COVID-19 fatigue and collateral impact of COVID-19 were important ethical challenges faced by the HCWs who completed the surveys. These experiences caused stress, anxiety, increased/decreased empathy, sleep disturbances, and feelings of helplessness. Respondents identified self-care and support provided by colleagues, family members, or friends as their main MD coping mechanisms. To a lesser extent, they also used formal sources of support provided by their employer and identified additional strategies they would like their employers to implement (e.g., improved access to mental health and wellness resources). These results may help inform pandemic policies for the future.
- 6 August 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (15) , 9701
Open AccessCOVID-19 Outbreak: Understanding Moral-Distress Experiences Faced by Healthcare Workers in British Columbia, Canada
Pandemic-management plans shift the care model from patient-centred to public-centred and increase the risk of healthcare workers (HCWs) experiencing moral distress (MD). This study aimed to understand HCWs’ MD experiences during the COVID-19 pandemic and to identify HCWs’ preferred coping strategies. Based on a qualitative research methodology, three surveys were distributed at different stages of the pandemic response in British Columbia (BC), Canada. The thematic analysis of the data revealed common MD themes: concerns about ability to serve patients and about the risks intrinsic to the pandemic. Additionally, it revealed that COVID-19 fatigue and collateral impact of COVID-19 were important ethical challenges faced by the HCWs who completed the surveys. These experiences caused stress, anxiety, increased/decreased empathy, sleep disturbances, and feelings of helplessness. Respondents identified self-care and support provided by colleagues, family members, or friends as their main MD coping mechanisms. To a lesser extent, they also used formal sources of support provided by their employer and identified additional strategies they would like their employers to implement (e.g., improved access to mental health and wellness resources). These results may help inform pandemic policies for the future.
- Open Access
- 30 September 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (5) , 3857-3865
CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada
Canada’s vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a framework that enables safe and regulatory compliant trial participation through local healthcare providers would benefit Canadian patients, clinicians, trial sponsors and the health care system. To address this issue, representatives of Canada’s cancer clinical trial community met to identify key challenges and develop recommendations for remote patient participation in trials. A structured literature review identified remote/rural trial delivery models. A panel of expert stakeholders reviewed the models and participated in a workshop to assess health system readiness, identify needed processes, tools and mechanisms, and develop recommendations for a Canadian framework for decentralized clinical trial conduct. The Canadian Remote Access Framework for clinical Trials (CRAFT) represents a risk-based approach used by site investigators to delegate responsibilities for a given trial to satellite health centres within a hub-and-spoke “trial cluster”. The Framework includes specific recommendations to ensure research experience, capacity, regulatory compliance and patient safety. Canada’s cancer care and telemedicine systems can be leveraged to enable broader access to clinical trials for patients who are geographically remote from cancer centres. CRAFT’s risk-based framework is based on other successful models of remote trial patient management and is in the pilot implementation phase in Canada.
- 30 September 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (5) , 3857-3865
Open AccessCRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada
Canada’s vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a framework that enables safe and regulatory compliant trial participation through local healthcare providers would benefit Canadian patients, clinicians, trial sponsors and the health care system. To address this issue, representatives of Canada’s cancer clinical trial community met to identify key challenges and develop recommendations for remote patient participation in trials. A structured literature review identified remote/rural trial delivery models. A panel of expert stakeholders reviewed the models and participated in a workshop to assess health system readiness, identify needed processes, tools and mechanisms, and develop recommendations for a Canadian framework for decentralized clinical trial conduct. The Canadian Remote Access Framework for clinical Trials (CRAFT) represents a risk-based approach used by site investigators to delegate responsibilities for a given trial to satellite health centres within a hub-and-spoke “trial cluster”. The Framework includes specific recommendations to ensure research experience, capacity, regulatory compliance and patient safety. Canada’s cancer care and telemedicine systems can be leveraged to enable broader access to clinical trials for patients who are geographically remote from cancer centres. CRAFT’s risk-based framework is based on other successful models of remote trial patient management and is in the pilot implementation phase in Canada.